

Imodium

TRADE MARK

loperamide hydrochloride

made to
measure
treatment for
acute and
chronic
diarrhoea

*The tailored dosage means that
patients only take Imodium when
they need it with no interruption to normal routine.
Imodium is easy to take and convenient to carry.*

*Designed for the specific control of
diarrhoea, Imodium relieves pain and
abdominal cramps rapidly and effectively.*

Imodium
simply
stops diarrhoea fast.

Further information is available from :



Janssen Pharmaceutica
2340 Beerse, Belgium

or from :

Janssen Pharmaceutical Limited,
Janssen House, Marlow, Bucks.

PL 0242/0028 PL 0242/0040

WHY NOT SUBSCRIBE TO THE SPECIALIST JOURNALS PUBLISHED BY THE BMA:—A SELECTION INCLUDES

Archives of Disease in Childhood, British Heart Journal, British Journal of Ophthalmology, Gut, Journal of Clinical Pathology & Journal of Neurology, Neurosurgery & Psychiatry.

FULL DETAILS OF SUBSCRIPTION RATES FROM BMA SPECIALIST PUBLICATIONS: BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR
TELEPHONE 01-387 4499 EXT. 309.

Thomas Kerfoot & Company Limited Merck Sharp & Dohme Limited Roche Products Limited



In an article published on 3rd December, 1979, the Daily Telegraph criticised leading pharmaceutical companies for sub-contracting the manufacture of their branded products to other smaller manufacturers who also make the generic equivalent to those products for sale by others. It was further suggested that pharmaceutical companies deceived the public and the medical profession by casting doubt on the safety of the generic equivalent of their branded products, whilst at the same time using the facilities of those smaller manufacturers to make their branded products.



MSD has invested more than £30m. in new manufacturing resources in the U.K. in the last five years.

MSD's plant at Cramlington is the first large-scale computerised pharmaceutical tabletting production unit in the world.

A new £16m. plant for producing fine chemicals for a new analgesic was opened at Enfield in October, 1979. One of the most advanced plants of its type in the world, it will supply diflunisal to the U.K. and all other markets outside the United States.

MSD's highly sophisticated plants ensure consistent therapeutic value to patients by rigid control of the composition and formulation of pharmaceutical products.

MSD is part of a group whose success is based on research (£86m. in 1979) and on the introduction of new products which represent genuine advances.

In support of this criticism, the article quoted Dr. Thomas Kerfoot of Thomas Kerfoot and Co. Ltd. who referred to his company's manufacture of Indocid for Merck Sharp & Dohme Limited and Valium for Roche Products Limited. In his letter to the Editor of the Daily Telegraph published on 7th December, Dr. Kerfoot acknowledged that this statement was false and, in the edition of 12th December, the Daily Telegraph expressed its regret for any embarrassment the article might have caused.

Dr. Kerfoot and Thomas Kerfoot and Co. Ltd. wish to express their sincere regret to Merck Sharp & Dohme Limited and Roche Products Limited for the false statements made about them and for the embarrassment and damage caused to them by the publication of the article in the Daily Telegraph.

By agreement with Merck Sharp & Dohme Limited and Roche Products Limited, Thomas Kerfoot and Co. Ltd. is placing this advertisement summarising each company's commitment to new investment in the U.K. and to the discovery of new products, which information has been supplied by Merck Sharp & Dohme Limited and Roche Products Limited respectively.



The Roche group has a strong commitment to research and in 1978 spent 13 per cent of its turnover on research and development which included substantial expenditure in the U.K.

Roche is at present extending its plant at Dalry to increase production and export of bulk vitamins and raw materials for pharmaceuticals.

The recent enhancement of the sterile production area at Roche's Welwyn plant is one example of the Company's continual efforts to ensure medicines of the highest standard and quality.

Over the last five years Roche has invested over £28m. on production, research and support facilities in the U.K.

Roche's extensive development programme for the future shows a continuing belief in the research for and discovery of new products to benefit Society.

**Have
you seen**

pharmacy international

trends in pharmacy
and pharmaceutical sciences

science for the professional in the 80's

a new approach

the first magazine to review the science of pharmacy and to supply scientific information and background on drugs, their effects, interactions and development, backed up by news, views and features on events in the pharmaceutical world.

a new perspective

striking a balance between the many divergent disciplines and interests, and forging international links among pharmacists in general practice, hospitals, industry, government and universities, PHARMACY INTERNATIONAL endeavours to place pharmacy in its true scientific perspective.

a new pharmacy

PHARMACY INTERNATIONAL reflects the growing unity amongst pharmacists world-wide – and takes pharmacy into the 80's as a cohesive and dynamic voice within science and medicine.

Subscription prices 1980

Personal edition (12 issues): U.K. £ 13.75 U.S.A. and Canada \$ 27.50 Europe Dfl. 55.00 Rest of the World Dfl. 58.50

Library edition (12 issues plus 1 annual compendium) Dfl. 140.00 + Dfl. 5.00 outside Europe, U.S.A., and Canada.

All prices include air delivery worldwide.

ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS

Send your orders or requests for free sample copy to:

In the U.S.A. and Canada: Journal Information Center Elsevier's Science Division 52 Vanderbilt Ave., New York, N.Y. 10017.

In the U.K. Elsevier/North-Holland Biomedical Press, 14A Regent Street, Cambridge CB2 1DB.

In all other countries: Elsevier/North-Holland Biomedical Press, P.O. Box 211, Amsterdam, The Netherlands.

PHARMACY INTERNATIONAL is published by Elsevier/North-Holland Biomedical Press in association with the Fédération Internationale Pharmaceutique and will be distributed to all members as part of their subscription.

British Council Medical Courses

PSYCHOGERIATRICS—THE CLINICAL AND ORGANISATIONAL PSYCHIATRY OF THE ELDERLY

13-25 July 1980 in Nottingham

The course will be held in the University of Nottingham. It will be directed by Professor T H D Arie who is Head of Nottingham University Department of Health Care of the Elderly (a joint department of psychiatrists, physicians and others concerned with the elderly). The course aims to review current practice in the clinical psychiatry of old age; recent clinical, laboratory and sociological developments; measurements of need, organisation of services and their evaluation. Emphasis will be given also to problems of institutional care; to the relationship between psychiatric and other medical and social services for old people; and to educational issues in this field. The course is designed primarily for psychiatrists, but doctors and members of other health professions with the requisite background would be welcome.

There are vacancies for 20 members.

Fee including full pension accommodation £560.

Please apply by 1 March 1980.

HIGHER MANAGEMENT IN THE HEALTH SERVICES

31 August-12 September 1980 in London

The aim of this course is to enable senior administrators to become acquainted with and discuss the critical issues vital to the delivery of health care within financial constraints. The Director of Studies will be Professor R F Logan of the Department of Community Health Organisation of Medical Care at the London School of Hygiene and Tropical Medicine where the course will be based. Professor R Kohn, Dr Hugh Sanderson and Dr Geoffrey Carroll will lead tutorial groups and workshops throughout the course. The course is intended for medical graduates with some years of experience specialising in public health, senior nursing officers, administrators with graduate training in management disciplines and research workers of senior lecturer or associate professor status. Members will be invited to contribute to the sessions particularly when taking part in syndicates and working groups.

There are vacancies for 35 members.

Fee including demi-pension accommodation £575.

Please apply by 15 April 1980.

RECENT ADVANCES IN OBSTETRICS AND GYNAECOLOGY

21 September-3 October 1980 in London

The Director of Studies will be Dr M de Swiet, Academic Sub-Dean, in association with Professor Sir John Dewhurst and Mr G V P Chamberlain of the Institute of Obstetrics and Gynaecology (University of London), Queen Charlotte's Maternity Hospital where the course will be based. The aim of the course is to present and discuss such recent advances in obstetrics and gynaecology in the United Kingdom. It is expected that the participants to the course will be able to contribute their own knowledge and opinions and ample time will be reserved for discussion. The course is designed for specialist obstetricians and gynaecologists in hospital practice with at least five years' experience.

There are vacancies for 50 members.

Fee including demi-pension accommodation £520.

Please apply by 30 April 1980.

Further information and application forms are available from local overseas Representatives of the British Council or from the Director, Courses Department, The British Council, 65 Davies Street, London W1Y 2AA, Britain.

ACUTE INJURY—CLINICAL MANAGEMENT, PATHOPHYSIOLOGY AND BIOCHEMISTRY

21 September-3 October 1980 in Glasgow and London

During this **two week** interdisciplinary course emphasis will be placed on the **acute** phase of injury of both surgical and traumatic origin but the **common** complications of sepsis and organ failure will also be covered. Practical problems of clinical management will be presented including advances in the nutritional aspects of the later phase of injury. Ample opportunity for active participation in discussion will be available at all sessions. The Directors of Studies will be Dr I McA Ledingham of the University Department of Surgery, Western Infirmary, Glasgow and Professor R G Clark of the Clinical Sciences Centre, Northern General Hospital, Sheffield. Members of the course will have an opportunity to visit a number of leading teaching hospitals and University Institutes in Glasgow and London. This course is intended for clinicians with an active interest in care of the acutely injured patient.

There are vacancies for 30 members.

Fee including full pension accommodation in Glasgow and demi-pension London £560.

Please apply by 2 May 1980.

ENDOCRINE TUMOURS

20-31 October 1980 in Cardiff

This course will present an integrated view of the structure and function of endocrine tumours. A major theme in the course will be the morphological diagnosis of endocrine tumours together with discussions of recent advances in laboratory investigations in endocrine diseases. The Director of Studies will be Professor Dillwyn Williams, Head of the World Health Organisation's Centre for Histological Classification of Endocrine Tumours and the Department of Pathology at the Welsh National School of Medicine. The assistant Director of Studies will be Dr Stewart Woodhead, Senior Lecturer in Medical Biochemistry at the Welsh National School of Medicine, University of Wales, Cardiff, where the course is based. The course is planned for Pathologists with an interest in endocrine pathology—both histopathologists and clinical pathologists. It will also be of value to other workers in the endocrine field with an interest in the correlation of structure and function in endocrine tumours.

There are vacancies for 30 members.

Fee including demi-pension accommodation £590.

Please apply by 6 June 1980.

CLINICAL AND DIAGNOSTIC VIROLOGY—NEWER TECHNIQUES AND ADVANCES

2-14 November 1980 in Birmingham

This course will place emphasis on the contribution of laboratory techniques to solving diagnostic problems in this field, the treatment of virus infections and the prevention of disease. Opportunity will be given for carrying out practical procedures in rapid diagnosis by immunofluorescence and electron microscopy both for respiratory and enteric virus infections (including scanning microscopy) and for carrying out laboratory investigations under Category A (total containment) conditions. For those not wishing to engage in practical laboratory work, ward rounds in the Infectious Diseases Unit will be available. The Director of Studies will be Dr T H Flewett, Director of the Regional Virus Laboratory, East Birmingham Hospital, where the course will be based. This course is intended to appeal to diagnostic and Public Health Virologists with more than five years experience as well as to senior clinicians with a special interest in infectious disease.

There are vacancies for 25 members.

Fee including demi-pension accommodation £585.

Please apply by 13 June 1980.

DON'T FORGET

As a fast acting diuretic

Burinex^{*} K

bumetanide and slow-release potassium chloride

is unbeatable...

as a potassium
supplement it's
unforgettable

Your patients rarely forget to take their 'water pill' but all too frequently fail to take their potassium supplement if you prescribe it separately.¹

Burinex K solves this problem because Burinex the 'most effective natriuretic agent'² 'coats' the potassium core - to make it truly unforgettable.

In addition - because of the shape and size - it's easier to swallow than the most commonly used potassium supplement alone.³

Burinex K in CCF right from the start

1. Brit. Med. J., 618, 2, 1977

2. Acta med. scand., 119, 193, 1973

3. J. Int. Res., 104, 3, 1976



Burinex K should be used with caution in patients with severe renal impairment, as the potassium chloride component may be excreted in the urine. Burinex K should not be used with potassium-sparing agents. Adverse reactions: Occasional skin rashes and mild gastric upset. Precautions: Burinex may potentiate antihypertensive therapy and rarely may affect carbohydrate metabolism. Periodic electrolyte checks are advisable on long-term therapy. Burinex K should be stopped immediately if signs or symptoms of bowel ulceration appear. Product Licence No: 0043/00276

^{*}Burinex is a trade mark



Leo Laboratories Limited

Full prescribing information available on request

Hayes Gate House, Hayes, Middx.